1.Tarantula cubensis extract alters the degree of apoptosis and mitosis in canine mammary adenocarcinomas.
Nilgun GULTIKEN ; Tolga GUVENC ; Duygu KAYA ; Ali Reha AGAOGLU ; Serhan Serhat AY ; Ibrahim KUCUKASLAN ; Birten EMRE ; Murat FINDIK ; Sabine SCHAFER-SOMI ; Selim ASLAN
Journal of Veterinary Science 2015;16(2):213-219
In the present study, 13 clinical cases of canine mammary adenocarcinoma were evaluated in order to understand the effect of Tarantula cubensis extract (TCE) on tumor tissue. Punch biopsies were taken from the tumors before treatment with TCE. Subcutaneous injections of TCE were administered three times at weekly intervals (3 mL per dog). Between days 7 and 10 after the third injection, the tumor masses were extirpated by complete unilateral mastectomy. Pre- and post-treatment tumor tissues were immunohistochemically assessed. The expression of B-cell lymphoma 2 (Bcl-2) was found to be higher in pre-treatment compared to post-treatment tissues (p < 0.01) whereas Ki-67 expression was lower in post-treatment tissues (p < 0.01). No significant differences in fibroblast growth factor or vascular endothelial growth factor expression were observed between pre- and post-treatment tissues (p > 0.05). The apoptotic index was determined to be low before treatment and increased during treatment. These results suggest that TCE may be effective for controlling the local growth of canine mammary adenocarcinoma by regulating apoptosis.
Adenocarcinoma/*drug therapy/physiopathology
;
Animals
;
Apoptosis/drug effects
;
Dog Diseases/*drug therapy/physiopathology
;
Dogs
;
Female
;
Mammary Neoplasms, Animal/*drug therapy/physiopathology
;
Mammary Neoplasms, Experimental/*drug therapy/physiopathology
;
Mitosis/drug effects
;
Spiders/*chemistry
2.Clinical use of a ceramide-based moisturizer for treating dogs with atopic dermatitis.
Ji Young JUNG ; Eui Hwa NAM ; Seol Hee PARK ; Seung Hee HAN ; Cheol Yong HWANG
Journal of Veterinary Science 2013;14(2):199-205
In humans, skin barrier dysfunction is thought to be responsible for enhanced penetration of allergens. Similar to conditions seen in humans, canine atopic dermatitis (CAD) is characterized by derangement of corneocytes and disorganization of intercellular lipids in the stratum corenum (SC) with decreased ceramide levels. This study was designed to evaluate the effects of a moisturizer containing ceramide on dogs with CAD. Dogs (n = 20, 3~8 years old) with mild to moderate clinical signs were recruited and applied a moisturizer containing ceramide for 4 weeks. Transepidermal water loss (TEWL), skin hydration, pruritus index for canine atopic dermatitis (PICAD) scores, and canine atopic dermatitis extent and severity index (CADESI) scores of all dogs were evaluated. Skin samples from five dogs were also examined with transmission electron microscopy (TEM) using ruthenium tetroxide. TEWL, PICAD, and CADESI values decreased (p < 0.05) and skin hydration increased dramatically over time (p < 0.05). Electron micrographs showed that the skin barrier of all five dogs was partially restored (p < 0.05). In conclusion, these results demonstrated that moisturizer containing ceramide was effective for treating skin barrier dysfunction and CAD symptoms.
Animals
;
Ceramides/*therapeutic use
;
Cholesterol/*therapeutic use
;
Dermatitis, Atopic/complications/drug therapy/physiopathology/*veterinary
;
Dog Diseases/*drug therapy/etiology/physiopathology
;
Dogs
;
Emollients/*therapeutic use
;
Epidermis/drug effects/physiopathology/ultrastructure
;
Fatty Acids, Nonesterified/*therapeutic use
;
Female
;
Male
;
Microscopy, Electron, Transmission/veterinary
;
Pruritus/drug therapy/etiology/physiopathology/veterinary
;
Republic of Korea
;
Ruthenium Compounds/chemistry
;
Water Loss, Insensible/drug effects